Skip to main content

Table 1 Baseline characteristics and plasma drug concentrations in pregnant women with pregnancy-associated primary toxoplasmosis and non-pregnant females with acute ocular toxoplasmosis, both assayed in the advisory laboratory using liquid chromatography–mass spectrometry (LC–MS)

From: Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case–control study

  OT PT p-value
Age
 N 17 89 p = 0.024a
 Mean ± SD [95% CI] 26.1 ± 5.3 [23.6; 28.5] 29.6 ± 6.0 [28.4; 30.9]
 Min–max 17–35 18.8–43.8
 Median 27 29.9
 Percentiles (25th; 75th) 21; 29 24.2; 33.6
PY (µg/l)
 N 17 89 p = 0.006b
 Mean ± SD 1550 ± 1411 838 ± 434
 Min–max 29–6160 29–2550
 Median [95% CI]d 1230 [780; 1890] 810 [745; 917]
 Percentiles (25th; 75th) 780; 1980 622; 1001
SA (mg/l)c
 N 17 89 p = 0.015b
 Mean ± SD 69.1 ± 44.2 44.5 ± 25.9
 Min–max 9.0–166.0 9.0–137.0
 Median [95% CI]d 70.4 [52.4; 89] 46.2 [39.9; 54.4]
 Percentiles (25th; 75th) 52.4; 89.0 21.8; 62.5
  1. a t-test for independent samples
  2. b Mann–Whitney U test
  3. c Detection limit set to 9.0 mg/l
  4. d 95% confidence intervals of the median were calculated using bootstrapping